Here are the top stories from the last week:

Industry Updates

CHPA disputes autism claims and defends acetaminophen safety
‍CHPA defends the safety of acetaminophen, citing decades of use and FDA safety reviews.
Read article »

ACS and NFL expand Crucial Catch initiative
‍The NFL has raised $35 million for ACS since 2009 through Crucial Catch-branded merchandise, auctions, and fundraising efforts.
Read article »

ACA subsidy expiration could cost providers $32 billion
‍Researchers warn that ending subsidies could threaten community care access and increase financial pressure on providers.
Read article »

Sanofi caps insulin costs at $35 nationwide
‍Sanofi has capped insulin costs at $35 nationwide, emphasizing that no one should struggle to afford their insulin.
Read article »

NACDS rejects PBM self-regulation proposal
‍NACDS has urged Congress to reject PBM self-regulation proposals, citing public demand for enforceable reforms.
Read article »

NCPA blasts gambit by PBMs to "self-regulate"
‍NCPA criticizes PBMs' self-regulation efforts, comparing it to letting criminals police themselves.
Read article »

White House reviews Trump's revived drug pricing rule
‍President Trump has set a deadline for pharma companies to align U.S. prices with global benchmarks, warning of regulatory action.
Read article »

CRN: Expanded HSA/FSA access may boost preventive care
‍A CRN analysis suggests that allowing dietary supplements under HSAs and FSAs would be cost-effective.
Read article »

Kentucky's strong PBM law is enforceable
‍Kentucky's Attorney General affirmed the enforceability of the state's PBM reform law, S.B. 188, which includes anti-steering provisions. This decision supports the regulation of PBMs affecting Kentucky residents, even if they are based out of state.
Read article »

Treatment & Technology Updates

Amneal submits BLA for Xolair biosimilar
‍Amneal has submitted a Biologics License Application to the FDA for a biosimilar to Novartis AG's Xolair, developed by Kashiv BioSciences. This biosimilar targets free IgE and is indicated for various conditions including asthma and chronic urticaria. The submission is a significant milestone for Amneal, positioning it for growth in the biosimilar market.
Read article »

Lupin receives FDA nod for generic Xarelto
‍Lupin has received FDA approval for a generic version of Xarelto, rivaroxaban for oral suspension. This medication is used for treating venous thromboembolism and thromboprophylaxis in pediatric patients. The market value for this generic is approximately $11 million.
Read article »

‍